评估非小细胞肺癌患者的长期生存的替代终点作为病理完整反应的评估:系统性审查和元分析
Chao Li1, Gaohaer Kadeerhan2, Tongtong Zhang3
1Pharmacy Department.
International journal of surgery (London, England)
|December 23, 2024
概括
在可切除的非小细胞肺癌 (NSCLC) 中,病理完整反应 (pCR) 与更好的生存率有关. 这项研究支持在临床试验中使用pCR作为替代终点来预测长期结果.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 病理完整反应 (pCR) 与无事件生存率 (EFS) 和整体生存率 (OS) 的改善有关.
- 在可切除非小细胞肺癌 (NSCLC) 的新辅助治疗试验中,PCR作为长期生存的替代终点的实用性仍在争论中.
研究的目的:
- 评估PCR在可切除NSCLC中的作用.
- 在临床试验中评估pCR作为EFS和OS的替代终点的可行性.
主要方法:
- 进行了对14项随机临床试验的元分析.
- 权重回归分析评估了pCR率与EFS和OS的危险比率 (HRs) 之间的关联.
- 替代值效应 (STE) 用于确定pCR对生存结果的预测值.
主要成果:
- 较高的pCR率与EFS (HR=0.69) 和OS (HR=0.82) 的显著改善相关.
- 在pCR和EFS (R2=0.76) 和OS (R2=0.54) 之间分别观察到强烈和中度的关联.
- 对于pCR的STEs是EFS的4.534和OS的10.278.
结论:
- 高的pCR率与可切除NSCLC的长期存活率有显著的改善有关.
- 这些发现支持使用pCR作为有效的替代终点来评估可切除NSCLC临床试验中的长期存活率.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
